Daniel L. Alkon - Nov 15, 2022 Form 4/A - Amendment Insider Report for Synaptogenix, Inc. (SNPX)

Role: President and Chief Scientific Officer, Director
Signature: /s/ Robert Weinstein, Attorney-in-fact
Stock symbol: SNPX
Transactions as of: Nov 15, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 12/1/2022, 06:49 PM
Date Of Original Report: Nov 17, 2022
Previous filing: Dec 1, 2022
Next filing: Dec 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNPX	Stock Option (Right to Buy)	Award	$0	+75K		$0.00	75K	Nov 15, 2022	Common Stock, par value $0.0001 per share	75K	$6.07	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This filing amends the Form 4, filed on November 17, 2022 by Mr. Alkon to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended.
F2	These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer.

Remarks:

President and Chief Scientific Officer